Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda reported positive Phase 3 results for oveporexton (TAK-861), an oral OX2R-selective agonist for narcolepsy type 1 (NT1). Two global, double-blind, placebo-controlled studies (FirstLight and RadiantLight) met all primary and secondary endpoints at week 12 with p-values <0.001 across doses (twice-daily 1mg and 2mg), showing statistically significant improvement in wakefulness, excessive daytime sleepiness, cataplexy frequency, symptom severity and quality of life.
The 12-week program enrolled 273 patients across 19 countries; more than 95% of completers entered the ongoing long-term extension. Oveporexton was generally well tolerated with no treatment-related serious adverse events reported; the most common adverse events were insomnia and urinary urgency/frequency. Takeda said these Phase 3 results do not have a significant impact on its consolidated forecast for the fiscal year ending March 31, 2026.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating the planned sale of 52,649 American Depositary Shares (ADSs) through Interactive Brokers.
- Aggregate market value: US$811,847.58
- Percentage of shares outstanding: ~0.04% of the company’s 123,490,548 ADSs outstanding
- Approximate sale date: 09 July 2025
- Security class: American Depositary Shares listed on the NYSE
- Acquisition source: The shares derive from restricted stock unit (RSU) awards that vested on 01 July 2025
- No prior sales were reported by the same holder during the preceding three-month period
The filing does not disclose the name of the selling shareholder, but Rule 144 requires that the seller affirm they possess no undisclosed material adverse information regarding Takeda. Because the volume represents a very small fraction of total outstanding ADSs, the transaction is unlikely to exert material pressure on the stock price. Nevertheless, investors often monitor Form 144 notices as early signals of insider disposition activity and potential sentiment shifts.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144, indicating the intent to sell up to 102,972 American Depositary Shares (ADSs) on or about 07 July 2025 through broker Interactive Brokers LLC. The proposed sale represents roughly 0.08 % of the company’s 123,490,548 ADSs outstanding and carries an aggregate market value of $1,587,828.24 (≈ $15.42 per ADS, calculated from the filing’s data).
The shares were acquired via restricted stock unit (RSU) awards that vested on 01 July 2025; no cash purchase was involved as the compensation-based grant constituted the consideration. The filer reports no prior sales during the past three months. According to Rule 144 requirements, the signer attests to possessing no undisclosed material adverse information and affirms compliance with Rule 10b5-1, if applicable.
While Form 144s do not guarantee that a transaction will occur, they give investors advance notice of potential insider or affiliate sales that could incrementally add to market supply. In this case, the planned volume is relatively small compared with total float, suggesting a minimal direct impact on liquidity or price, though insider sales can sometimes influence sentiment.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 disclosing a proposed sale of 18,622 American Depositary Shares (ADSs) with an aggregate market value of $287,151.24. The shares—acquired through vested restricted stock units on 1 July 2025—represent less than 0.02% of the outstanding 123,490,548 ADSs. The transaction is slated for approximately 9 July 2025 on the NYSE and will be executed through Interactive Brokers LLC. No other insider sales have been reported in the past three months.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating the proposed sale of 40,919 American Depositary Shares (ADSs) through Interactive Brokers on or about 07 July 2025. The aggregate market value of the planned sale is US$630,970.98, representing approximately 0.03 % of the company’s 123,490,548 ADSs outstanding. The shares derive from restricted stock unit (RSU) awards that vested on 01 July 2025 and are being sold for the account of an unnamed insider. No other sales have been reported by this person in the past three months, and the filer affirms there is no undisclosed material adverse information regarding the issuer.
The filing is procedural and signals an intent—not a completed transaction—allowing the insider to sell restricted or control securities under Rule 144. Given the limited size relative to Takeda’s float and market capitalization, the disclosure is generally viewed as immaterial to the company’s fundamental outlook.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating an intended sale of 58,559 American Depositary Shares (ADSs), representing approximately 0.05 % of the company’s 123,490,548 ADSs outstanding. The proposed transaction is valued at US $902,979.78 based on the market price at the time of filing and is expected to take place on or about 07 / 09 / 2025 through NYSE, with Interactive Brokers LLC acting as broker.
The shares stem from restricted stock units that vested on 07 / 01 / 2025. The filer reports no sales of Takeda securities in the preceding three months. By signing the notice, the seller certifies the absence of undisclosed material adverse information about Takeda and affirms compliance with Rule 144 and, if applicable, any Rule 10b5-1 trading plan.
While the dollar amount is modest relative to Takeda’s market capitalization, Form 144 filings alert investors to potential insider activity that could influence near-term trading volume and sentiment.